• • Sapacitabine clinical trials • • Sapacitabine clinicalprogress trials in • • • •

solid and tumors malignancies advanced hematological sapacitabine oral Cyclacel’s with combination in with combination in non AML elderly in treatment line second in combination with combination in cutaneous T - (NSCLC) cancer celllung small SAPACITABINE WINTER 2019 arrest in G2/M in arrest treatment resulting in apo in resulting berepaired cannot are and and arrest synthesis, DNA affects Sapacitabine Mechanism of Action analogue a BCL2 inhibitor BCL2 a with combination ce convenien preclinical Sapacitabine Selected Clinical Studies in Patients with Solid Tumors activity. anticancer demonstrated have CNDAC and , primary After cell cells machinery repair DNA DNA strand single causing first by synthesis cancer susceptible to cell death induced by induced death cell to susceptible recombination repair (HR) defects pathway particularly are cells DNA methylation, ATM, CDK, CHK1, DNA CHK1, CDK, ATM, methylation, DNA including repair, and DNA survival checkpoints, cycle cell of inhibitors other with ations combin support data Preclinical PARP a with collaboration a (Cyclacel’s 1 seliciclib with sequentially administered sapacitabine Sapacitabine* PARP - cell lymphoma (CTCL) cell lymphoma alternating with in AML elderly with decitabine alternating

subsequently subsequently . death triggers triggers

- sapacitabine to susceptibility enhanced show . Cells with homologous homologous with Cells . class its of drugs among

oral oral inhibitors activity is mediated by is mediated activity

metabolite CNDAC. Both sapacitabine, as an oral mechanism mechanism unique a with its its into converted is sapacitabine administration

data delay st apoptosis apoptosis is developing , Cyclacel developing is -

- generation, oral CDK2/7/9 inhibitor), in in inhibitor), CDK2/7/9 oral generation,

CDK CDK (CYC682) (CYC682) 20

, unmet medical need and need medical unmet , . phase . ,5,6 2,3,4

s

Ph (IST) cancer breast BRCA+ in ,

closed DNA Damage Response (DDR) Program S that that breaks strand double to converted e.g. mutated BRCA1 and BRCA2, cancer BRCA2, and BRCA1 mutated e.g.

inhibitor. in advanced advanced in

phase

In the background of defective DNA DNA defective of background the In ( programmed programmed or is an orally an is

progression progression MDS MDS

inhibitor inhibitor Phase 1 evaluation of of evaluation 1 Phase

CDKi (Completed) Ph1b/2

interference interference

and through through and in leukemias - ptosis available, nucleoside nucleoside available,

sapacitabine in in sapacitabine of action cancer against sapacitabine. cell cell in breast cancer. cancer. breast in and causes causes and

Ph1

- . death)

PK 7 oral oral

the s

Ph Sapacitabine Sapacitabine with DNA DNA with breaks ,

HDAC dosing dosing

cell cycle cycle cell . Ph2 - anti Its 1 ,

induced induced

Base which which and and Ph2 Ph3 Ph2

1b/2 1/2 d on d on

responders responders patients. sporadic). No CR or PR was 1 and germline (44 mutation BRCA for positive tested cancer pancreatic and ovarian breast, with patients and 5PR 10st CR, In the study. parts of two first the in observed was activity Anticancer damage. DNA of marker a with biopsies skin in observed was mechanism enhance and damage DNA augment to is regimen this of objective treated heavily Phase 1 Sapacitabine Single Agent in R/R AML/MDS. Selected Clinical Studies in Hematological Malignancies MDS. 47 to administered was sapacitabine trial, clinical escalation dose 1 Phase clinical benefit clinical a from Data PARP inhibitors was associated with lack of benefit. of lack with associated was inhibitors PARP inhibitor agents platinum ed with treat patients the of half patients, naïve inhibitor data Phase 1 in solid tumors. cycles. 7 of average an receiving disease stable achieved 4 mg, 75 to 50 from dosing daily twice with treated patients 15 Among cycles. 10 of average an receiving disease stable 10 and PR achieved 2 mg, 175 to 100 from dosing daily once with treated patients 25 Among inhibitor concomitantly sapacitabine of Meeting. Annual 16 andASCO 21weeks. at the presented Data were 2016 responders cancer pancreatic and weeks were reported at the 2018 AACR 2018 the at reported mutationsBRCA1/2 were in 20 efficacy intestinal stromal tumor (G tumor stromal intestinal gastro with patient A female tumors. solid advanced with all 124 to administered was sapacitabine trials one least at receiving after ed progress who 25 in study 2 evaluated were Phase 2 in NSCLC. achieved SD for 50 months on sapacitabine treatment. sapacitabine on months 50 for SD achieved part

formed CR CR s

1

- sapacitabine induced apoptosis induced sapacitabine benefit or or naïve patients with BRCA mutant breast cancer. breast mutant BRCA with patients naïve Treatment duration for breast/ovarian cancer cancer breast/ovarian for duration Treatment and and (1 CRp CRp

part 1 expansion coh expansion 1 part Phase the of basis the patients with NSCLC treated below MTD MTD below treated NSCLC with patients patients with metastatic breast cancer and breast cancer metastatic with patients

2 CR and 2 and CR

, rate rate

(n=67) i The The ongoing. is patients cancer advanced ed w 8 n

able disease able

as Phase Phase a of portion escalation dose the Once and twice daily dosing schedules schedules dosing daily twice and Once .

patients with advanced leukemias or or leukemias advanced with patients was was 30% of Progression on previous platinum or or platinum previous on Progression

achieved in 6 patients. 6 in achieved

% 35.6 of rate control disease PR) PR)

In three Phase 1 dose escalation escalation dose 1 Phase three In

IST) refractory to refractory IST)

observed ranged between 54 and >240 and 54 between ranged and one on previous PARP PARP previous on one and ) with with

in in observed was observed ort to assess safety and and safety assess to ort 1b/2 breast cancer IST cancer breast 1b/2 olaparib olaparib

in BRCA wild in BRCA .

. A (2 PR) Proof of

ll eight PARP PARP eight ll prior prior In addition, 7 addition, In previously previously

in PARP PARP in imatinib imatinib - comers between between 45 regimen - type type

9 who who

The The . ( 1

A In a 10

-

.

patients achieved bone marrow CRi.15 The Company believes that it has defined a patient population for whom the sapacitabine regimen may Phase 2 Sapacitabine Single Agent in AML. 60 AML patients represent an improvement over low intensity treatment aged 70 or older who were untreated or in first relapse by decitabine alone. were randomly allocated to treatment with one of 3 schedules of sapacitabine in 28 day cycles: (A) 200 mg bid Sapacitabine-venetoclax combination study in AML. FDA for 7 days, (B) 300 mg bid for 7 days and (C) 400 mg bid for 3 granted accelerated approval to venetoclax in elderly days for 2 weeks. Treatment with (C), the dosing schedule patients with newly-diagnosed AML unfit for intensive used in the SEAMLESS Phase 3, resulted in 1-year survival of induction .16 Cyclacel is enrolling relapsed 30%, OS of 213 days, durable CR of 25% and ORR of 45% (5 or refractory AML/MDS patients in a Phase 1 study at MD CR, 1 CRi and 3 hematological improvement).13 Anderson to explore the safety and efficacy of a sapacitabine-venetoclax combination as an oral regimen. Phase 2 Sapacitabine Single Agent in MDS after HMA. In 63 Preclinical data support potential synergy of the patients aged 60 years and older with MDS who had combination in AML models. progressed or relapsed after treatment with HMA, OS ranged from 227 to 291 days and one year survival from in Breast Cancer 24% to 38%. 48% of patients received 4 or more cycles. For Sapacitabine-PARP inhibitor. Investigators from the 41/63 patients with 10% or more blasts in their bone Department of Breast Cancer, Dana-Farber Cancer marrow OS was 291 days (~ 9 months). Mortality rate from Institute are enrolling patients with BRCA mutant all causes within 30 days of randomization was 5%.14 metastatic breast cancer in a Phase 1b/2 investigator- Pilot/Lead-in Sapacitabine Alternating with Decitabine. sponsored trial (IST) evaluating an oral combination of Forty-six newly diagnosed AML patients aged 70 or older sapacitabine and olaparib (PARP inhibitor). Cyclacel and were administered the same regimen as the experimental AstraZeneca are providing investigational drugs for this arm in SEAMLESS. Thirty day mortality from all causes was study. 4% and 60-day 13%. OS was 238 days (~ 8 months), 1-year Endnotes: survival 35% and overall response rate (ORR) 41% (10 CR, 4 * Sapacitabine (CYC682 or CS-682) is an experimental drug under clinical PR and 5 major hematological improvement). For patients investigation. It is not approved for human use. HMA=hypomethylating 75 years or older, median overall survival (OS) was 263 days, agent ( or decitabine). 1 Liu, X, et al, Blood, 2010:116:1737-46. one year survival 36%. Fifty nine per cent of patients 2 Frame, S, et al, Abstract 761, EHA 2009. received 5 or more cycles.12 3. Green, S, et al, Abstract 4552, AACR 2009. 4. Shapiro, G, et al, Abstract LB-202, AACR 20135. Pivotal Trial in Hematological Malignancies 5. Liu, X, et al, Mol Cancer Ther, 2016; 15: 2302–13. 6. Liu, X, et al, Cancer Chemother Pharmacol, 2018; 81: 255-267. Sapacitabine alternating with HMA (decitabine). 7. Liu, X, et al, Expert Opin Investig Drug, 2012; 21: 541-55. 8. Tolaney, S, et al, J Clin Oncol 34, 2016 (suppl; abstr 2503). SEAMLESS, a pivotal Phase 3 trial of sapacitabine in front- 9. Keenan T, et al, ASCO 2019; poster# CT050 line acute myeloid (AML) enrolled 482 elderly 10. Cyclacel data on file. patients unfit for chemotherapy. An experimental arm of 11. Kantarjian, H, et al, ASH 2017, Blood 130: Abstract 891. 12. Kantarjian H et al. ASH 2012. Abstract 2630. oral sapacitabine administered in alternating cycles with 13. Kantarjian, H, et al, The Lancet Oncology, 2012; 13:1096-104. intravenous decitabine was compared with a control arm of 14. Garcia-Manero, G, et al, Abstract 2752, ASH 2013. 15. Kantarjian, H, et al, J Clin Oncol, 2009; 28:285-91. intravenous decitabine. As reported at the 2017 ASH 16. Venclexta® (venetoclax tabs) prescribing information, accessed 11/18. conference SEAMLESS did not reach statistically significant superiority in OS, although an improvement in CR rate was Contact Information observed in the ITT population. In the stratified subgroup of Cyclacel Pharmaceuticals, Inc. www.cyclacel.com patients with low baseline peripheral white blood cell count (NASDAQ: CYCC; NASDAQ: CYCCP) [email protected] (2/3rds of the study), an improvement in OS was observed 200 Connell Drive #1500 1 James Lindsay Place for the investigational arm. The opposite was true for Berkeley Heights, NJ 07922 Dundee DD1 5JJ, UK patients with high white blood cell count.11 +1 (908) 517-7330 +44 (1382) 206 062

Regulatory Discussions © Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are Cyclacel Pharmaceuticals, Inc. trademarks. Following submission of statistical and exploratory analyses This document contains forward-looking statements within the meaning of the “safe of the SEAMLESS data, Cyclacel has received national harbor” provisions of the Private Securities Litigation Reform Act of 1995 about scientific advice from three European regulatory authorities financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- with regard to a potential approval pathway. looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. A number of factors could cause actual results and developments to differ materially and are discussed under "Risk Factors" in our quarterly and annual reports filed with the SEC. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.